| scholarly article | Q13442814 |
| P2093 | author name string | Alessandra Fantauzzi | |
| Ivano Mezzaroma | |||
| P2860 | cites work | Life expectancy of recently diagnosed asymptomatic HIV-infected patients approaches that of uninfected individuals | Q22242705 |
| Life expectancy of individuals on combination antiretroviral therapy in high-income countries: a collaborative analysis of 14 cohort studies | Q24597052 | ||
| Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach | Q26859055 | ||
| Novel therapeutic strategies targeting HIV integrase | Q27003960 | ||
| Structural and Functional Analyses of the Second-Generation Integrase Strand Transfer Inhibitor Dolutegravir (S/GSK1349572) | Q27670616 | ||
| Rapid and durable antiretroviral effect of the HIV-1 Integrase inhibitor raltegravir as part of combination therapy in treatment-naive patients with HIV-1 infection: results of a 48-week controlled study | Q28242324 | ||
| Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells | Q28369295 | ||
| Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators | Q29547281 | ||
| Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials | Q31108441 | ||
| Pharmacokinetics and safety of S/GSK1349572, a next-generation HIV integrase inhibitor, in healthy volunteers | Q33559015 | ||
| Dolutegravir in antiretroviral-experienced patients with raltegravir- and/or elvitegravir-resistant HIV-1: 24-week results of the phase III VIKING-3 study | Q33880221 | ||
| Inhibition of human immunodeficiency virus type 1 isolates by the integrase inhibitor L-731,988, a diketo Acid | Q34144064 | ||
| Safety and efficacy of dolutegravir in treatment-experienced subjects with raltegravir-resistant HIV type 1 infection: 24-week results of the VIKING Study | Q34316681 | ||
| Once-daily dolutegravir versus twice-daily raltegravir in antiretroviral-naive adults with HIV-1 infection (SPRING-2 study): 96 week results from a randomised, double-blind, non-inferiority trial | Q34373867 | ||
| Integrase inhibitors to treat HIV/AIDS. | Q34397376 | ||
| Pharmacokinetic enhancement of inhibitors of the human immunodeficiency virus protease by coadministration with ritonavir. | Q35134071 | ||
| Potential benefit of dolutegravir once daily: efficacy and safety | Q36603416 | ||
| Dolutegravir in antiretroviral-naive adults with HIV-1: 96-week results from a randomized dose-ranging study | Q36959425 | ||
| The activity of the integrase inhibitor dolutegravir against HIV-1 variants isolated from raltegravir-treated adults | Q37244858 | ||
| Clinical pharmacokinetic, pharmacodynamic and drug-interaction profile of the integrase inhibitor dolutegravir | Q37248656 | ||
| Long-acting injectable antiretrovirals for HIV treatment and prevention | Q37272776 | ||
| Protease inhibitor monotherapy. | Q37819920 | ||
| Once-daily single-tablet regimens: a long and winding road to excellence in antiretroviral treatment. | Q38029534 | ||
| Next-generation integrase inhibitors : where to after raltegravir? | Q38081866 | ||
| The quad pill, a once-daily combination therapy for HIV infection | Q38142803 | ||
| Antiretroviral regimens sparing agents from the nucleoside(tide) reverse transcriptase inhibitor class: a review of the recent literature | Q38170576 | ||
| Elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate single-tablet regimen (Stribild®): a review of its use in the management of HIV-1 infection in adults | Q38171345 | ||
| Dolutegravir: a new integrase strand transfer inhibitor for the treatment of HIV. | Q38172029 | ||
| Dolutegravir (S/GSK1349572) exhibits significantly slower dissociation than raltegravir and elvitegravir from wild-type and integrase inhibitor-resistant HIV-1 integrase-DNA complexes | Q38627271 | ||
| Lopinavir/ritonavir combined with raltegravir or tenofovir/emtricitabine in antiretroviral-naive subjects: 96-week results of the PROGRESS study | Q39394695 | ||
| Characterization of the R263K mutation in HIV-1 integrase that confers low-level resistance to the second-generation integrase strand transfer inhibitor dolutegravir | Q39421000 | ||
| Dolutegravir plus abacavir-lamivudine for the treatment of HIV-1 infection | Q39570904 | ||
| Antiviral activity, safety, and pharmacokinetics/pharmacodynamics of dolutegravir as 10-day monotherapy in HIV-1-infected adults | Q39734035 | ||
| TMC114, a novel human immunodeficiency virus type 1 protease inhibitor active against protease inhibitor-resistant viruses, including a broad range of clinical isolates | Q40417023 | ||
| The M50I polymorphic substitution in association with the R263K mutation in HIV-1 subtype B integrase increases drug resistance but does not restore viral replicative fitness | Q41884057 | ||
| In Vitro antiretroviral properties of S/GSK1349572, a next-generation HIV integrase inhibitor | Q42111140 | ||
| Resistance mutations against dolutegravir in HIV integrase impair the emergence of resistance against reverse transcriptase inhibitors | Q42241128 | ||
| Biochemical analysis of the role of G118R-linked dolutegravir drug resistance substitutions in HIV-1 integrase | Q42265700 | ||
| Safety and feasibility of treatment simplification to atazanavir/ritonavir + lamivudine in HIV-infected patients on stable treatment with two nucleos(t)ide reverse transcriptase inhibitors + atazanavir/ritonavir with virological suppression (Atazana | Q42276740 | ||
| Dolutegravir versus raltegravir in antiretroviral-experienced, integrase-inhibitor-naive adults with HIV: week 48 results from the randomised, double-blind, non-inferiority SAILING study | Q42285688 | ||
| In vitro investigations into the roles of drug transporters and metabolizing enzymes in the disposition and drug interactions of dolutegravir, a HIV integrase inhibitor. | Q42714414 | ||
| Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials | Q42839639 | ||
| Durable efficacy and safety of raltegravir versus efavirenz when combined with tenofovir/emtricitabine in treatment-naive HIV-1-infected patients: final 5-year results from STARTMRK. | Q43451461 | ||
| Once-daily dolutegravir versus raltegravir in antiretroviral-naive adults with HIV-1 infection: 48 week results from the randomised, double-blind, non-inferiority SPRING-2 study | Q44304694 | ||
| Simplification to dual antiretroviral therapy including a ritonavir-boosted protease inhibitor in treatment-experienced HIV-1-infected patients | Q45075780 | ||
| Implications of integrase inhibitors for HIV-infected transplantation recipients: raltegravir and dolutegravir (S/GSK 1349572). | Q45991778 | ||
| HIV monotherapy with ritonavir-boosted protease inhibitors: a systematic review | Q46180060 | ||
| Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection | Q46466415 | ||
| Once daily dolutegravir (S/GSK1349572) in combination therapy in antiretroviral-naive adults with HIV: planned interim 48 week results from SPRING-1, a dose-ranging, randomised, phase 2b trial | Q58000796 | ||
| Cross-resistance Profile of the Novel Integrase Inhibitor Dolutegravir (S/GSK1349572) Using Clonal Viral Variants Selected in Patients Failing Raltegravir | Q58228900 | ||
| Factors associated with complete adherence to HIV combination antiretroviral therapy | Q83881805 | ||
| Dual raltegravir/etravirine combination in virologically suppressed HIV-1-infected patients on antiretroviral therapy | Q84919973 | ||
| P433 | issue | 4 | |
| P921 | main subject | dolutegravir | Q937224 |
| P304 | page(s) | 164-177 | |
| P577 | publication date | 2014-07-01 | |
| P1433 | published in | Therapeutic advances in chronic disease | Q26842871 |
| P1476 | title | Dolutegravir: clinical efficacy and role in HIV therapy | |
| P478 | volume | 5 |
| Q37095708 | 3-Hydroxypyrimidine-2,4-dione-5-N-benzylcarboxamides Potently Inhibit HIV-1 Integrase and RNase H. |
| Q40517770 | A Two-Way Steady-State Pharmacokinetic Interaction Study of Doravirine (MK-1439) and Dolutegravir |
| Q56794669 | Cellulose Acetate Phthalate and Antiretroviral Nanoparticle Fabrications for HIV Pre-Exposure Prophylaxis |
| Q40695098 | Integrase Strand Transfer Inhibitors (INSTIs) Resistance Mutations in HIV-1 Infected Turkish Patients |
| Q64988862 | Treatment Guidelines for the Use of Antiretroviral Agents in HIV-Infected Adults and Adolescents: An Update. |
Search more.